Watshara Shoombuatong, Philip Prathipati, Veda Prachayasittikul, Nalini Schaduangrat, Aijaz Ahmad Malik, Reny Pratiwi, Sompon Wanwimolruk, Jarl E. S. Wikberg, Matthew Paul Gleeson, Ola Spjuth and Chanin Nantasenamat*
Mateus F. Alves, Marcus T. Scotti, Mayara B. Felix, Hamilton M. Ishiki, Cinthia Rodrigues Melo, Frederico F. Ribeiro, Josean F. Tavares, José M.B. .Filho, Kardilândia M. de Oliveira, Andrea F. R. de Paula, Francisco J. B. Mendonça Jr., Luciana Scotti*, Alexandre R. da Paz, Sócrates G. dos Santos and Margareth de F. F. M. Diniz
Michael W. Sinz, Ph.D. is Director of Metabolism and Pharmacokinetics at Bristol Myers Squibb where he manages ADmezME lead optimization in drug discovery. Dr. Sinz previously held the position of Section Director-Pharmacokinetics and Drug Metabolism for Parke-Davis/Pfizer. He received B.S. degrees in Chemistry (ACS) and Biology from the University of Wisconsin-Eau Claire and a Ph.D. in Pharmacognosy/Medicinal Chemistry from the University of Minnesota (2001). He is editor in chief of Current Drug Metabolism and associate editor of Drug Metabolism Letters. Dr. Sinz’s resume includes an extensive number of peer reviewed publications, book chapters, and external presentations both locally and internationally.